Cómo citar
Resumen
El síndrome genitourinario en la menopausia está conformado por síntomas vulvovaginales y vesicouretrales, que son consecuencia de cambios epiteliales producidos por el hipoestrogenismo característico de esta etapa. Su diagnostico es clínico y se establece a partir de síntomas y signos pélvicos y genitourinarios, en un contexto de menopausia o hipoestrogenismo perimenopáusico El tratamiento consta de dos pilares: uno de primera línea, de tipo no hormonal, y uno de segundo línea, a base de hormonas en las que resaltan las bajas dosis de estrógenos tópicos.
Palabras clave
Citas
Gloria Bachmann, MD, Richard J Santen, MD. Clinical manifestations and diagnosis of genitourinary syndrome of menopause (vulvovaginal atrophy). Uptodate: Robert L Barbieri, MD. [Internet]; 2019. [Consultado 11 de febrero 2020]. Disponible en: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-genitourinary-syndrome-of-menopause-vulvovaginal-atrophy?search=atrofia%20vaginal&source=search_result&selectedTitle=2~113&usage_type=default&display_rank=2#references
Panay N. Genitourinary syndrome of the menopause - dawn of a new era? Climacteric 2015;18(1):13-17. https://doi.org/10.3109/13697137.2015.1070564
Kathryn A Martin, MD,Robert L Barbieri, MD. Treatment of menopausal symptoms with hormone therapy. Uptodate: William F Crowley, Jr, MD. [Internet];2019 [Consultado 11 Febrero 2020]. Disponible en: https://www.uptodate.com/contents/treatment-of-menopausal-symptoms-with-hormone-therapy?search=terapia%20de%20reemplazo%20hormonal%20para%20mujeres%20menop%C3%A1usicas%20adultas&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
Robert F Casper, MD. Clinical Manifestations and diagnosis of menopause. Uptodate: Robert L Barbieri, MD, William F Crowley, Jr, MD. [Internet]: 2019. [Consultado 11 febrero 2020]. Disponible en https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-menopause?search=terapia%20de%20reemplazo%20hormonal%20para%20mujeres%20menop%C3%A1usicas%20adultas&source=search_result&selectedTitle=7~150&usage_type=default&display_rank=7
Lev-Sagie A. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations. Clin Obstet Gynecol. 2015;58(3):476-91. https://doi.org/10.1097/GRF.0000000000000126
Edwards D, Panay N.Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151-61. https://doi.org/10.3109/13697137.2015.1124259
Krychman M, Graham S, Bernick B, et al. The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate. J Sex Med 2017; 14:425. https://doi.org/10.1016/j.jsxm.2017.01.011
Huang AJ, Gregorich SE, Kuppermann M, et al. Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause 2015; 22:144. https://doi.org/10.1097/GME.0000000000000281
Gloria Bachmann, MD, Richard J Santen, MD.Treatment of genitourinary syndrome of menopause (vulvovaginal atrophy). Uptodate: Robert L Barbieri, MD [Internet]; 2019 [Consultado 11 Febrero al 2020]. Disponible en: https://www.uptodate.com/contents/treatment-of-genitourinary-syndrome-of-menopause-vulvovaginal-atrophy?search=terapia%20de%20reemplazo%20hormonal%20para%20mujeres%20menop%C3%A1usicas%20adultas&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#references,//
Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 2016; 215:704. https://doi.org/10.1016/j.ajog.2016.07.045
Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: the AGATA study. AGATA study Menopause. 2016; 23(10):1139-45.https://doi.org/10.1097/GME.0000000000000675
Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas 2016;91:42-50. https://doi.org/10.1016/j.maturitas.2016.05.015
Baber RJ, Panay N, Fenton A, et al. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19:109-50. https://doi.org/10.3109/13697137.2015.1129166
Diagnosis and management of menopause: summary of NICE guidance.Sarri G, Davies M, Lumsden MA, Guideline Development Group.BMJ. 2015; 351:h5746. https://doi.org/10.1136/bmj.h5746
ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2018; 123:202. Reafirmado 2018. https://doi.org/10.1097/01.AOG.0000441353.20693.78
Strandberg KL, Peterson ML, Lin YC, et al. Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. Antimicrob Agents Chemother 2010; 54:597. https://doi.org/10.1128/AAC.01151-09
Jan L Shifren, MD. Overview of sexual dysfunction in women: Management.Uptodate: Robert L Barbieri, MD. [Internet]; 2019 [Consultado 11 Febrero al 2020]. Disponible en: https://www.uptodate.com/contents/overview-of-sexual-dysfunction-in-women-management?search=estrogenos%20topicos&source=search_result&selectedTitle=10~150&usage_type=default&display_rank=10#H1220789776
Baber RJ, Panay N, Fenton A, et al. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19:109-50. https://doi.org/10.3109/13697137.2015.1129166
Mueck AO, Ruan X, Prasauskas V, Grob P, Ortmann O. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric. 2018;21(2):140-147. https://doi.org/10.1080/13697137.2017.1421923
Shen J, Song N, Williams CJ, et al. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep 2016;6:24380. https://doi.org/10.1038/srep24380
Vaneechoutte M. The human vaginal microbial community. Res Microbiol 2017;168:811-25. https://doi.org/10.1016/j.resmic.2017.08.001
Anahtar MN, Byrne EH, Doherty KE, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 2015;42:965-76. https://doi.org/10.1016/j.immuni.2015.04.019
Kim YH, Park S, Lee M, et al. Effect of a pH-Balanced Vaginal Gel on Dyspareunia and Sexual Function in Breast Cancer Survivors Who Were Premenopausal at Diagnosis: A Randomized Controlled Trial. Obstet Gynecol 2017; 129:870. https://doi.org/10.1097/AOG.0000000000001988
A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.Biehl C, Plotsker O, Mirkin S. Menopause. 2019; 26(4):431-453. https://doi.org/10.1097/GME.0000000000001221
Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause 2018; 25:11. https://doi.org/10.1097/GME.0000000000000956
Emily S Lukacz, MD, MAS. Treatment of urinary incontinence infemales. Uptodate: Linda Brubaker, MD, FACOG, Kenneth E Schmader, MD. [Internet]; 2019 [Consultado 14 Febrero al 2020]. Disponible en: https://www.uptodate.com/contents/treatment-of-urinary-incontinence-in-females?search=estrogenos%20topicos&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=4#H16614846
Lethaby A, Ayeleke RO, Roberts H. Local estrogenfor vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500. https://doi.org/10.1002/14651858.CD001500.pub3
Constantine G, Millheiser LS, Kaunitz AM, et al. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia. Menopause 2019;24:409-16 https://doi.org/10.1097/GME.0000000000000786
Constantine G, Simon JA, Pickar JH, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause 2017;24:409-16. https://doi.org/10.1097/GME.0000000000000786
Thomas M Hooton, MD, Kalpana Gupta, MD, MPH. Recurrent simple cistitis in women. Uptodate: Stephen B Calderwood, MD[Internet]; 2019 [Consultado 14 Febrero al 2020]. Disponible en: https://www.uptodate.com/contents/recurrent-simple-cystitis-in-women?search=vaginal%20estrogen&source=search_result&selectedTitle=10~129&usage_type=default&display_rank=10#H3844951368
Emily S Lukacz, MD, MAS. Treatment of urgency incontinence/overactive bladder in females. Uptodate: Linda Brubaker, MD, FACOG, Kenneth E Schmader, MD. [Internet]; 2019 [Consultado 14 Febrero al 2020]. Disponible en: https://www.uptodate.com/contents/treatment-of-urgency-incontinence-overactive-bladder-in-females?search=vaginal%20estrogen&source=search_result&selectedTitle=7~129&usage_type=default&display_rank=7
Rahn DD, Ward RM, Sanses TV, et al. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J 2015; 26:3. https://doi.org/10.1007/s00192-014-2554-z
Constantine GD, Simon JA, Pickar JH, Archer DF, Bernick B, Graham S, Mirkin S. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. Curr Med Res Opin. 2018;34(12):2131-2136. https://doi.org/10.1080/03007995.2018.1527578
Wendy Y Chen, MD, MPH. Menopausal hormone therapy and the risk of breat cancer. Uptodate: Robert L Barbieri, MD, William F Crowley, Jr, MD, Joann G Elmore, MD, MPH. Robert L Barbieri, MD [Internet]; 2018 [Consultado 11 Febrero al 2020]. Disponible en: https://www.uptodate.com/contents/menopausal-hormone-therapy-and-the-risk-of-breast-cancer?search=terapia%20de%20reemplazo%20hormonal%20para%20mujeres%20menop%C3%A1usicas%20adultas&source=search_result&selectedTitle=5~150&usage_type=default&display_rank=5
Kathryn A Martin, MD, Robert L Barbieri, MD. Preparations for menopausal hormone therapy. Uptodate: Peter J Snyder, MD, William F Crowley, Jr, MD. [Internet]; 2019 [Consultado 11 Febrero al 2020]. Disponible en: https://www.uptodate.com/contents/preparations-for-menopausal-hormone-therapy?search=terapia%20de%20reemplazo%20hormonal%20para%20mujeres%20menop%C3%A1usicas%20adultas&source=search_result&selectedTitle=6~150&usage_type=default&display_rank=6
Archer DF, Constantine GD, Simon J, et al. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. Menopause 2017;24:510-16. https://doi.org/10.1097/GME.0000000000000790
Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019;20(7):821-835. https://doi.org/10.1080/14656566.2019.1574752
The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24:409-16. https://doi.org/10.1097/GME.0000000000000921
Long ME, Faubion SS, MacLaughlin KL, et al. Contraception and hormonal management in the perimenopause. J Womens Health (Larchmt) 2015; 24:3. https://doi.org/10.1089/jwh.2013.4544
Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas 2016;91:42-50. https://doi.org/10.1016/j.maturitas.2016.05.015
FDA Warns Against Use of Energy-Based Devices to Perform Vaginal 'Rejuvenation' or Vaginal Cosmetic Procedures: FDA Safety Communication. [Internet]; 2019 [Consultado 14 Febrero al 2020]. Disponible en: https://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm615013.htm
Martel C, Labrie F, Archer DF, et al. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol 2016; 159:142. https://doi.org/10.1016/j.jsbmb.2016.03.016
Labrie F, Bélanger A, Pelletier G, et al. Science of intracrinology in postmenopausal women. Menopause 2016; 23:719
Ke Y, Labrie F, Gonthier R, et al. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration. J Steroid Biochem Mol Biol 2015; 154:186. https://doi.org/10.1016/j.jsbmb.2015.08.016
Johansen N, Lindén Hirschberg A, Haase Moen M. The role of testosterone in menopausal hormone treatment. What is the evidence? Acta Obstet Gynecol Scand. 2020. https://doi.org/10.1111/aogs.13819
Melisko ME, Goldman ME, Hwang J, et al. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 2017; 3:313. https://doi.org/10.1001/jamaoncol.2016.3904
Eigeliene N, Kangas L, Hellmer C, et al. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause 2016; 23:719. https://doi.org/10.1097/GME.0000000000000624
The 2017 hormone therapy position statement of The North American Menopause Society.The NAMS 2017 Hormone Therapy Position Statement Advisory Panel.Menopause. 2017; 24(7):728-753. https://doi.org/10.1097/GME.0000000000000921
Structure of Epithelial and Stromal Compartments of Vulvar and Vaginal Tissue From Women With Vulvo-Vaginal Atrophy Taking Ospemifene.Alvisi S, Baldassarre M, Gava G, Mancini I, Gagliardi M, Seracchioli R, Meriggiola MC. J Sex Med. 2018; 15(12):1776-1784. https://doi.org/10.1016/j.jsxm.2018.10.009
Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015; 18:226. https://doi.org/10.3109/13697137.2014.954996
Goldstein I, Simon JA, Kaunitz AM, et al. Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices. Menopause 2019; 26:994. https://doi.org/10.1097/GME.0000000000001350
Bruyniks, N, Biglia, N, Palacios, S et al. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric. 2017; 20: 195-204
https://doi.org/10.1080/13697137.2017.1284780
Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. Archer DF, Altomare C, Jiang W, Cort S. Menopause. 2017; 24(10):1167-1174. https://doi.org/10.1097/GME.0000000000000900
Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials. Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV. J Womens Health (Larchmt). 2018; 27(1):14-23. https://doi.org/10.1089/jwh.2017.6385
Reid RL, Black D, Derzko C, Portman D. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause. J Obstet Gynaecol Can. 2020;S1701-2163(19)30981-8.
Ruan X, Mueck AO. Impact of smoking on estrogenic efficacy. Climacteric 2015;18:38-46. https://doi.org/10.3109/13697137.2014.929106
Hunter MM, Nakagawa S, Van Den Eeden SK, et al. Predictors of impact of vaginal symptoms in postmenopausal women. Menopause 2016; 23:40. https://doi.org/10.1097/GME.0000000000000482
Barton DL, Sloan JA, Shuster LT, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 2018; 26:643. https://doi.org/10.1007/s00520-017-3878-2
Barton DL, Shuster LT, Dockter T, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer 2018; 26:1335. https://doi.org/10.1007/s00520-017-3960-9
Melisko ME, Goldman ME, Hwang J, et al. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol 2017; 3:313. https://doi.org/10.1001/jamaoncol.2016.3904
Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause 2018; 25:11 https://doi.org/10.1097/GME.0000000000000956
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2020 Array